National Health Investors (NHI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual meeting scheduled for May 27, 2026, with voting available online, by mail, or in person.
Shareholders are encouraged to review proxy materials and vote by May 26, 2026.
Voting matters and shareholder proposals
Election of seven directors is up for shareholder vote.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other matters that arise at the meeting.
Board of directors and corporate governance
Board recommends voting for all seven director nominees: Robert W. Chapin, Jr., Tracy M.J. Colden, Lilly H. Donohue, James R. Jobe, Robert A. McCabe, Jr., D. Eric Mendelsohn, and Candice W. Todd.
Partial view of Summaries dataset, powered by Quartr API
Latest events from National Health Investors
- Q2 2026 featured strong SHOP growth, higher net income, and a major $560M portfolio sale.NHI
Q2 2026 - Strong 2025 results, strategic shift to private pay housing, and all proposals approved.NHI
AGM 2026 - Q1 2026 saw robust FFO growth, major SHOP expansion, and a $560M portfolio sale pending.NHI
Q1 2026 - $560M asset sale boosts private pay housing, deleverages, and simplifies governance.NHI
M&A Presentation - 2025 saw robust growth, board refreshment, enhanced governance, and expanded ESG initiatives.NHI
Proxy filing - Strong SHOP and FFO growth in 2025; 2026 outlook supported by robust investments and industry trends.NHI
Q4 2025 - SHOP occupancy and NOI surged, but net income and FFO per share declined; liquidity remains strong.NHI
Q3 2024 - FFO and FAD rose on strong rent collections and occupancy, while net income declined 11%.NHI
Q2 2024 - Q4 and 2024 results surpassed guidance, with strong FFO, FAD, and SHOP growth and a positive 2025 outlook.NHI
Q4 2024